Crinetics Pharmaceuticals, Inc.
CRNX
$35.75
-$0.30-0.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.82M | -130.09M | -115.64M | -96.77M | -80.60M |
| Total Depreciation and Amortization | 994.00K | 1.01M | 959.00K | 925.00K | 788.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.65M | 19.86M | 22.23M | 16.93M | 15.44M |
| Change in Net Operating Assets | 9.27M | -1.50M | 6.60M | -9.54M | -2.51M |
| Cash from Operations | -92.90M | -110.72M | -85.85M | -88.45M | -66.87M |
| Capital Expenditure | -458.00K | -863.00K | -3.20M | -1.24M | -1.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.57M | 165.67M | 41.16M | -84.72M | -541.06M |
| Cash from Investing | 57.11M | 164.81M | 37.95M | -85.96M | -542.09M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.04M | 3.08M | 7.06M | 4.44M | 555.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 967.00K |
| Cash from Financing | 26.04M | 3.08M | 7.06M | 4.44M | 556.24M |
| Foreign Exchange rate Adjustments | -106.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.87M | 57.18M | -40.84M | -169.98M | -52.72M |